Kymera Therapeutics, Inc. announced on June 26, 2025, the pricing of its underwritten public offering, totaling $250.8 million. The offering includes 5,044,500 shares of common stock priced at $44.00 per share, and 655,500 pre-funded warrants at $43.9999 per warrant.
The gross proceeds to Kymera from the offering are expected to be approximately $250.8 million, before deducting underwriting discounts and commissions and estimated offering expenses. The company has also granted the underwriters a 30-day option to purchase up to an additional 855,000 shares of common stock.
The offering is expected to close on June 30, 2025, subject to customary closing conditions. Kymera intends to use the net proceeds to continue advancing its pipeline of preclinical and clinical degrader programs, which are designed to address large patient populations, and for general corporate purposes and working capital.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.